VIDEO: Study investigates use of oncolytic measles virus to treat pediatric brain tumors

ByCassie Kline, MD, MAS

ByGeorgia I Salvaryn

Fact checked byMindy Valcarcel, MS

PHILADELPHIA — In this video, Cassie Kline, MD, MAS, discusses the results of the PNOC005 trial she presented at International Symposium on Pediatric Neuro-Oncology.

The phase 1 trial investigated the “safety and tolerability of intratumoral or intrathecal administration of oncolytic measles virus in children and young adults with recurrent medulloblastoma or atypical teratoid/rhabdoid tumor,” according to the abstract.

“[O]ncolytic viruses are certainly an exciting way in which we want to think about utilizing either a virus itself or a virus as an immune-stimulatory agent against central nervous system tumors,” Kline, a pediatric neuro-oncology attending and director of neuro-oncology clinical research at Children’s Hospital of Philadelphia, said.

Reference:

Kline C, et al. Abstract TRLS-11. Presented at: International Symposium on Pediatric Neuro-Oncology; June 28-July 2, 2024; Philadelphia.

Published by:

Sources/Disclosures

Collapse

Disclosures: Kline reports grants from and/or clinical trial contracts with Bristol Myers Squibb, Cannonball Kids’ cancer Foundation, Chimerix, Curis, Day One Biopharmaceuticals, Ipsen, Kazia Therapeutics, Kortney Rose Foundation, Midatech Pharma and Regeneron Pharmaceuticals.

Take Homes from ISPNO

Read more

VIDEO: Study investigates use of oncolytic measles virus to treat pediatric brain tumors

Reference:

Related Content